...
首页> 外文期刊>Cancer Immunology, Immunotherapy >Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer
【24h】

Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer

机译:整合素αvbeta6促进结直肠癌的肿瘤耐受性

获取原文
           

摘要

Tumor immune tolerance plays a critical role in tumor cell survival; the establishment of tumor immune tolerance is incompletely understood yet. Integrin alphavbeta6 (avb6) is involved in tumor growth and metastasis. This study aimed to observe the effect of avb6 on the development of tumor tolerance in colorectal cancer (CRC). In this study, 28 CRC patients were recruited. The frequencies of tolerogenic dendritic cells (TolDC), regulatory T cells (Treg), and CD8+ T cells in surgically removed CRC tissue were assessed by flow cytometry. The levels of avb6 in CRC tissue were measured by enzyme-linked immunoassay (ELISA). The effect of avb6 on inducing TolDCs and Tregs was evaluated with the cell culture model. The results showed that in surgically removed CRC tissue, we detected higher frequencies of TolDC and Tregs, lower frequency CD8+ T cells and high levels of avb6 as compared with non-CRC tissue. CRC protein extracts could induce TolDC development that could be blocked by anti-avb6 antibody. CRC-derived DCs could convert naïve CD4+ T cells to Tregs. Peripheral CD8+ T cells from CRC patients still retained the ability to produce granzyme B and to proliferate in response to CRC tumor antigen in culture that was abolished by the presence of CRC-derived Tregs. We conclude that CRC-derived avb6 is involved in the establishment of tumor immune tolerance in local tissues.
机译:肿瘤免疫耐受在肿瘤细胞存活中起着至关重要的作用。尚未完全了解肿瘤免疫耐受的建立。整联蛋白αvbeta6(avb6)参与肿瘤的生长和转移。这项研究旨在观察avb6对结直肠癌(CRC)肿瘤耐受性发展的影响。在这项研究中,招募了28名CRC患者。通过流式细胞术评估手术切除的CRC组织中耐受性树突状细胞(TolDC),调节性T细胞(Treg)和CD8 + T细胞的频率。 CRC组织中avb6的水平通过酶联免疫法(ELISA)进行测量。使用细胞培养模型评估了avb6对诱导TolDCs和Tregs的影响。结果显示,与非CRC组织相比,在通过手术切除的CRC组织中,我们检测到TolDC和Tregs的频率更高,而CD8 + T细胞的频率更低,而avb6的水平更高。 CRC蛋白提取物可以诱导TolDC发育,而该过程可能会被抗avb6抗体阻断。 CRC衍生的DC可以将幼稚的CD4 + T细胞转化为Treg。来自CRC患者的外周CD8 + T细胞仍然保留产生粒酶B的能力,并能在培养物中对CRC肿瘤抗原做出反应而增殖,这种能力已因CRC衍生的Treg的存在而被废除。我们得出的结论是,CRC衍生的avb6参与了局部组织中肿瘤免疫耐受的建立。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号